Terry S. Thomas
Known title: DirectorCIK: 0001822379
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
Flowers Foods faces recall and BNP Paribas downgrade. Flowers Foods is navigating an allergen recall that may impact its 'Better For You' brand image. Compounding this, BNP Paribas maintained an Underperform rating and lowered its price target to $5. The stock currently trades near its 52-week low, reflecting these ongoing challenges.
Transaction History
| MKC | ▼ Sell | Other | 4 | $196 | 4/28/2026 | View on chart |
| FLO | ▲ Buy | Grant | 34,617 | $0 | 2/25/2026 | View on chart |
| FLO | ▼ Sell | Tax Withholding | 8,428 | $81K | 2/25/2026 | View on chart |
| MKC | ▲ Buy | Option Exercise | 2,222 | — | 2/15/2026 | View on chart |
| MKC | ▼ Sell | Other | 3 | $191 | 1/13/2026 | View on chart |
| FLO | ▼ Sell | Tax Withholding | 1,365 | $14K | 1/5/2026 | View on chart |
| FLO | ▼ Sell | Tax Withholding | 1,476 | $15K | 1/5/2026 | View on chart |
| FLO | ▲ Buy | Grant | 41,770 | $0 | 1/4/2026 | View on chart |
| MKC | ▼ Sell | Other | 3 | $177 | 10/28/2025 | View on chart |
| MKC | ▼ Sell | Other | 2 | $176 | 7/22/2025 | View on chart |
| MKC | ▼ Sell | Other | 2 | $168 | 4/21/2025 | View on chart |
| MKC | ▲ Buy | Option Exercise | 1,344 | $0 | 3/15/2025 | View on chart |
| FLO | ▼ Sell | Tax Withholding | 6,596 | $124K | 2/13/2025 | View on chart |
| MKC | ▼ Sell | Other | 2 | $175 | 1/13/2025 | View on chart |
| FLO | ▼ Sell | Tax Withholding | 1,365 | $27K | 1/5/2025 | View on chart |
| FLO | ▲ Buy | Grant | 15,080 | $0 | 12/29/2024 | View on chart |
| MKC | ▼ Sell | Other | 2 | $162 | 10/21/2024 | View on chart |
| MKC | ▼ Sell | Other | 2 | $161 | 7/22/2024 | View on chart |
| FLO | ▼ Sell | Open Market | 36,577 | $845K | 3/11/2024 | View on chart |
| FLO | ▼ Sell | Tax Withholding | 6,788 | $150K | 2/13/2024 | View on chart |
| MKC | ▲ Buy | Grant | 383 | $25K | 1/23/2024 | View on chart |
| FLO | ▲ Buy | Grant | 13,960 | $0 | 12/31/2023 | View on chart |
| FLO | ▲ Buy | Grant | 54,250 | $0 | 9/1/2023 | View on chart |
| FLO | ▲ Buy | Option Exercise | 1,980 | $0 | 8/31/2023 | View on chart |
| FLO | ▲ Buy | Option Exercise | 5,300 | $0 | 5/25/2023 | View on chart |
| FLO | ▲ Buy | Option Exercise | 6,050 | $0 | 5/26/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 4, 2026
McCormick Analysts Lower Targets After Q3 Results
McCormick shares have come under pressure as several analysts, including UBS and TD Cowen, lowered their price targets following third-quarter results. While BNP Paribas maintained a positive outlook, the broader trend reflects reduced expectations for near-term growth. The company has also replaced its auditor with KPMG and reaffirmed its overall financial outlook despite the recent stock decline.
McCormick Analysts Lower Targets After Q3 Results. McCormick shares have come under pressure as several analysts, including UBS and TD Cowen, lowered their price targets following third-quarter results. While BNP Paribas maintained a positive outlook, the broader trend reflects reduced expectations for near-term growth. The company has also replaced its auditor with KPMG and reaffirmed its overall financial outlook despite the recent stock decline.